Autologous Stem Cell Transplant (ASCT)

PROCEDURE8 trials

Conditions

Diffuse Large B-Cell LymphomaMultiple MyelomaMultiple Myeloma ProgressionMultiple Myeloma With Failed RemissionMultiple Myeloma in RelapsePrimary Central Nervous System LymphomaRefractory CancerRelapsed Cancer

Phase 1

Tinostamustine Conditioning and Autologous Stem Cell

TerminatedNCT03687125

Mundipharma-EDO GmbHMultiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma With Failed Remission

Start: 2018-10-15End: 2019-04-17Updated: 2021-06-18

Phase 2

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

CompletedNCT01453205

MedImmune LLCDiffuse Large B-Cell Lymphoma

Start: 2012-02-27End: 2016-07-11Updated: 2018-03-12

A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation

TerminatedNCT02112045

Washington University School of MedicineMultiple Myeloma

Start: 2015-01-20End: 2019-09-10Updated: 2019-11-26

Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma

Active, not recruitingNCT02315716

University College, LondonMultiple Myeloma

Start: 2015-06-16End: 2029-11-30Updated: 2024-12-06

2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)

WithdrawnNCT03003728

University of ArkansasMultiple Myeloma

Start: 2019-11-01End: 2020-07-08Updated: 2020-07-10

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

Active, not recruitingNCT04268498

University of MiamiMultiple Myeloma

Start: 2020-02-11End: 2027-02-01Updated: 2026-03-24

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Active, not recruitingNCT04802356

PETHEMA FoundationMultiple Myeloma

Start: 2021-04-07End: 2026-06-01Target: 50Updated: 2026-03-05

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

RecruitingNCT05681195

Baptist Health South FloridaPrimary Central Nervous System Lymphoma, Refractory Cancer, Relapsed Cancer +1

Start: 2024-04-25End: 2033-02-01Target: 15Updated: 2026-03-03

Blood2025-11-03

Disease burden by NGS in bone marrow and peripheral blood samples at baseline and after frontline therapy: Subgroup analysis of the advance randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood2025-11-03

Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial.

Journal of Clinical Oncology2025-05-286 citations

Efficacy of pemetrexed-based regimens in primary central nervous system lymphoma: A single-center experience.

Journal of Clinical Oncology2025-05-281 citations

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma

Blood Advances2024-11-226 citations

Long-Term Effects of Belantamab Mafodotin Plus Bortezomib, Lenalidomide and Dexamethasone (VRd) on T Cell Exhaustion Phenotype

Blood2024-11-051 citations

Advance Multicenter Clinical Trial: MRD-Driven Therapy in Newly Diagnosed Multiple Myeloma Patients

Blood2024-11-051 citations

Advance Multicenter Clinical Trial: MRD-Driven Therapy in Newly Diagnosed Multiple Myeloma Patients

Blood2023-11-026 citations

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.

2022-12-1515 citations

Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial

Blood2022-11-158 citations

Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).

Journal of Clinical Oncology2021-05-205 citations

A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Blood2018-11-29

Autologous Stem Cell Transplant (ASCT)

Sponsors

Conditions

Phase 1

Phase 2

Related Papers